07.30.26 -- What It's Like To Advance A Cell Therapy Through The Japan Entry Acceleration Program

Review 2025’s gap between AI discovery and trial execution, highlighting legislative and FDA shifts to help sponsors operationalize participant experience for 2026.

Investigational products present a distinctly high-risk environment for labeling and barcoding. Explore best practices for barcoding solutions that allow for improved medication safety in clinical trials.

Explore key regulatory considerations across major global markets to support more efficient early-phase clinical development planning.

Global submissions are getting faster—and more complex. Explore a 7-step framework for aligning FDA and EMA pathways to reduce risk, duplication, and regulatory delays.

Emerging psychiatric therapies bring hope, but progress is fragile. Biomarker-driven, mechanism-first approaches help overcome biological, regulatory, and commercial barriers.

Targeted Protein Degraders are a revolutionary drug class with challenges in bioavailability and formulation complexity. Strategic CDMO partnerships are key to successful, scalable development.

The shifting dynamics of clinical research from the current funding dynamic to the increased complexity of drug development, requires a different approach to functional outsourcing to be successful.

Complex oncology trials require deep science, regulatory expertise, and coordination. See how integrated teams and adaptive designs speed startup, protect patients, and scale.